Trump and Biden Both Hate Pharma—Investors Shouldn't
The drug sector just had one of its worst years ever relative to the S&P 500 and now faces political attacks, but investors should focus on the value.
Source: livemint.com
📰 Will Sevush News
Will Sevush News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Will Sevush. Real-time updates on events, politics, business and more.
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
In pharma, a company can take a larger slice of the healthcare pie than peers, but it is still constrained by the size of the pie.
Source: livemint.com
Never Mind Covid, Investors Want a Pfizer Obesity Pill
The pharmaceutical company’s silence on oral obesity drug worries investors
Source: wsj.com
Eli Lilly, Pfizer, and Others Are Working on Weight-Loss Pills. What to Know.
Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills—easier to take, cheaper to make—might have the biggest long-term impact.
Source: marketwatch.com
Lilly, Pfizer and Others Are Working on Obesity Pills. What to Know.
Lilly investors are upbeat on injectable weight-loss treatment Mounjaro, but the pills—easier to take, cheaper to make—might have the biggest long-term impact.
Source: marketwatch.com
Biotech ETFs Could Be in for More Pain Ahead
After suffering one of their worst Aprils in years, biotech sector-related exchange traded funds could be in for even more pain ahead.
Christopher Raymond Piper Sandler Darren Chervitz Jacob Discovery Fund Shares Nasdaq Biotechnology Will Sevush
Source: etftrends.com